Kare Schultz - Nov 1, 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
President and CEO, Director
Signature
/s/ Dov Bergwerk as attorney-in-fact for Kare Schultz
Stock symbol
TEVA
Transactions as of
Nov 1, 2022
Transactions value $
$0
Form type
4
Date filed
11/2/2022, 08:55 AM
Previous filing
May 6, 2022
Next filing
Jul 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +116K +8.16% 1.54M Nov 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -116K -100% $0.00* 0 Nov 1, 2022 Ordinary Shares 116K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on November 3, 2017 with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vested on November 1, 2022.